Radiosensitization of a mouse tumor model by sustained intra-tumoral release of Etanidazole and Tirapazamine using a biodegradable polymer implant device
- 1 October 1999
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 53 (1), 77-84
- https://doi.org/10.1016/s0167-8140(99)00123-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude miceRadiation Oncology Investigations, 1998
- Hypoxia-specific cytotoxins in cancer therapySeminars in Radiation Oncology, 1996
- The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trialJournal of Neuro-Oncology, 1995
- Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomasThe Lancet, 1995
- SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumoursBritish Journal of Cancer, 1993
- Final report of the phase I trial of continuous infusion etanidazole (SR 2508): A radiation therapy oncology group studyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomasJournal of Neurosurgery, 1991
- Intratumoural administration of cisplatin in slow-release devicesCancer Chemotherapy and Pharmacology, 1990
- Intratumoral and parametrial infusion of metronidazole in the radiotherapy of uterine cervix cancer: Preliminary reportInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Clinical perspectives for the use of new hypoxic cell sensitizersInternational Journal of Radiation Oncology*Biology*Physics, 1982